Zevra Therapeutics, Inc. (ZVRA) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $0.00; Notes PayableUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $0.00; Notes PayableUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $61.93M; Notes PayableUSD (m); Long-term DebtUSD $61.93M; Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD (m); Notes PayableUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $0.00.
Zevra Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Notes Payable USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium), Net USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Convertible Notes Payable, Current USD | Long-term Line of Credit USD | Convertible Notes Payable USD | Line of Credit Facility, Maximum Amount Outstanding During Period USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Line of Credit Facility, Remaining Borrowing Capacity USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $61.93M | (m) | $61.93M | (m) | (m) | (m) | (m) | (m) | $63.61M | $755.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | $0.00 | $0.00 | $0.00 | $63.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $61.31M | (m) | $61.31M | $0.00 | $0.00 | $0.00 | $63.09M | $0.00 | $63.09M | $801.00K | $1.78M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $60.69M | (m) | $60.69M | $0.00 | $0.00 | $0.00 | $62.57M | $0.00 | $62.57M | $843.00K | $1.87M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $60.09M | $60.09M | (m) | (m) | (m) | (m) | (m) | (m) | $62.05M | $883.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $59.50M | (m) | $59.50M | (m) | (m) | (m) | (m) | (m) | $61.55M | $921.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $59.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $58.90M | $58.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $959.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $58.33M | $58.33M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $938.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $5.07M | $5.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-148.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $12.80M | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $20.00M | $7.20M |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $12.80M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | $20.00M | $7.20M |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $12.80M | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | $20.00M | $7.20M |
| 2022-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $20.00M | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $68.20M | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $67.66M | (m) | (m) | (m) | (m) | (m) | $68.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $781.00K | (m) | $65.92M | (m) | (m) | (m) | (m) | (m) | $67.09M | (m) | (m) | $65.92M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $781.00K | (m) | $67.27M | (m) | (m) | (m) | (m) | (m) | $69.02M | (m) | (m) | $67.27M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $68.61M | (m) | (m) | (m) | (m) | (m) | $70.93M | (m) | (m) | $68.61M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $77.34M | (m) | (m) | (m) | (m) | (m) | $80.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $80.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $6.72M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $6.50M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $6.37M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $81.44M | (m) | (m) | (m) | (m) | (m) | $83.34M | (m) | (m) | $3.33M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $3.33M | $3.33M | $76.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.33M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.33M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.33M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.33M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $92.73M | $3.33M | $3.33M | $3.33M | $86.25M | (m) | $96.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.93M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.65M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.37M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.10M | $50.00K | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $50.00K | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $50.00K | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $325.00K | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $50.00K | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $50.00K | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |